Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, and Sanofi signed Most Favored Nation pricing agreements with the Trump administration on December 19, marking what a senior White House official described as a shift from “initial
This report summarises the key issues impacting prices across a range of categories in Pharma and Biopharma industry as of September 2023. Some of the macro trends impacting pricing in September 2023 include: This is in the context of global
Life sciences supply chains are moving out of China. This trend briefing, powered by SmartCube, summarises the key points you need to know.
Jim Fries, CEO of Rx-360 gives an overview of Supply Chain integrity and why it’s more important than ever. Supply Chain Integrity and Security (SCIS) is defined as a set of policies, procedures, and technologies used to provide visibility and traceability of products within the
Briefing In a significant development within the field of diabetes research, Eli Lilly, a leader in pharmaceutical innovation, has announced its acquisition of Sigilon Therapeutics, in the pursuit of a functional cure for Type 1 diabetes (T1D). The acquisition, valued
Briefing . Astellas Pharmaceuticals has unveiled its plans to establish an Open Innovation Hub at Mitsui Fudosan’s “MITSUI LINK-Lab KASHIWA-NO-HA 1. The Open Innovation Hub The Open Innovation Hub, located at Mitsui Fudosan’s “MITSUI LINK-Lab KASHIWA-NO-HA 1,” will serve as
Vertex Pharmaceuticals and Lonza have recently announced a strategic collaboration aimed at supporting the manufacturing of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with Type 1 Diabetes. The 130,000ft² site will be run
Two new partnerships will enable Croda to provide its clients with sustainable and eco-friendly versions of two commonly used adjuvants by the vaccine industry: Squalene and QS-21. Croda International Plc has signed an agreement with Amyris an Botanical Solutions (BSI)
Eli Lilly has made a significant move in its quest to revolutionize autoimmune disease treatment. The company announced its acquisition of Dice Therapeutics, a leading innovator in the development of therapies targeting autoimmune disorders $2.4 Billion USD. Briefing Eli Lilly’s
In a bold move following in the footsteps of Merck, Bristol Myers Squibb has filed a groundbreaking lawsuit challenging certain provisions of the Inflation Reduction Act. Bristol Myers Squibb (BMS) alleges that the Inflation Reduction Act’s measures, which empower Medicare
